Inhibrx Biosciences (INBX) Common Equity (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Common Equity for 3 consecutive years, with $8.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Common Equity fell 94.02% year-over-year to $8.0 million; the TTM figure through Dec 2025 stood at $8.0 million (down 94.02% YoY), while the FY2025 annual figure was $8.0 million, down 94.02% from the prior year.
• Common Equity eased to $8.0 million in Q4 2025 per INBX's latest filing, from $36.8 million in the prior quarter.
• Across five years, Common Equity topped out at $219.4 million in Q2 2024 and bottomed at -$24.8 million in Q2 2023.
• Historically, Common Equity has averaged $81.7 million across 3 years, with a median of $68.6 million in 2025.
• Annual changes were most pronounced in 2024 — Common Equity jumped 984.11% — and 2025, when it plunged 94.02%.
• Inhibrx Biosciences' Common Equity stood at $43.5 million in 2023, then surged by 207.07% to $133.6 million in 2024, then slumped by 94.02% to $8.0 million in 2025.
• Business Quant data shows INBX's Common Equity at $8.0 million in Q4 2025, $36.8 million in Q3 2025, and $68.6 million in Q2 2025.